GlassScriptPhysician profile
Brianna Robison
NPI 1568001709
$1,187.92
in general payments reported to CMS, 2019-2025
22 companies · $308 in 2025
The $308 reported for 2025 was more than what a typical Physician Assistant provider received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $411 · 2022: $181 · 2023: $145 · 2024: $143 · 2025: $308.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $596.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $595.69 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $186.51 | 2021-2025 | |
| Organon LLC | $118.16 | 2022-2025 | Nexplanon |
| Exeltis, USA INC. | $103.76 | 2021-2025 | Slynd |
| Hologic Sales and Service, LLC | $99.79 | 2021-2025 | Novasure, Myosure Tissue Removal Device, Fluent Fluid Management System |
| Myovant Sciences INC. | $96.12 | 2021-2022 | |
| Astellas Pharma US INC | $79.84 | 2023-2025 | Veozah |
| Sumitomo Pharma America, INC. | $66.55 | 2023-2025 | Myfembree, Gemtesa |
| Coopersurgical, INC. | $53.40 | 2021-2025 | Paragard T 380a |
| Evofem Biosciences, INC. | $49.77 | 2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $47.90 | 2021-2022 | |
| Pharmacosmos Therapeutics INC. | $47.16 | 2021 | |
| Daiichi Sankyo INC. | $40.57 | 2021 | |
| Averitas Pharma INC. | $24.86 | 2024 | Qutenza |
| Mayne Pharma Commercial LLC | $24.81 | 2022-2023 | |
| Therapeuticsmd, INC. | $24.40 | 2021 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Agile Therapeutics, INC. | $23.77 | 2021 | |
| Coloplast Corp | $18.97 | 2025 | |
| Aspira Women'S Health INC | $18.44 | 2021 | |
| Novo Nordisk INC | $16.73 | 2024 | |
| Biogen, INC. | $15.85 | 2025 | Zurzuvae |
| Mylan Pharmaceuticals INC. | $15.71 | 2021 | |
| C. R. Bard, INC. & Subsidiaries | $14.85 | 2024 | Bd Onclarity |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Brianna Robison listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.